Background-Clinical trial and epidemiological data support that the cardiovascular effects of estrogen are complex, including a mixture of both potentially beneficial and harmful effects. In animal models, estrogen protects females from vascular injury and inhibits atherosclerosis. These effects are mediated by estrogen receptors (ERs), which, when bound to estrogen, can bind to DNA to directly regulate transcription. ERs can also activate several cellular kinases by inducing a rapid nonnuclear signaling cascade. However, the biological significance of this rapid signaling pathway has been unclear. Methods and Results-In the present study, we develop a novel transgenic mouse in which rapid signaling is blocked by overexpression of a peptide that prevents ERs from interacting with the scaffold protein striatin (the disrupting peptide mouse). Microarray analysis of ex vivo treated mouse aortas demonstrates that rapid ER signaling plays an important role in estrogen-mediated gene regulatory responses. Disruption of ER-striatin interactions also eliminates the ability of estrogen to stimulate cultured endothelial cell migration and to inhibit cultured vascular smooth muscle cell growth. The importance of these findings is underscored by in vivo experiments demonstrating loss of estrogen-mediated protection against vascular injury in the disrupting peptide mouse after carotid artery wire injury. Conclusions-Taken together, these results support the concept that rapid, nonnuclear ER signaling contributes to the transcriptional regulatory functions of ER and is essential for many of the vasoprotective effects of estrogen. These findings also identify the rapid ER signaling pathway as a potential target for the development of novel therapeutic agents.
of cardiovascular disease (CVD) in age-matched premenopausal women compared with men but a near equalization of CVD risk in women after menopause, suggesting that endogenous estrogen protects women against CVD. Clinical trials of postmenopausal estrogen therapy, however, demonstrate mixed CVD effects. These findings underscore the complexity of the cardiovascular effects of estrogen and support the need for a better understanding of the molecular mechanisms by which estrogen regulates cardiovascular biology. In vivo animal-based studies, including those in the mouse, have shown that estrogen protects against both vascular injury (reducing medial hyperplasia and vascular smooth muscle cell [VSMC]growth) and atherosclerosis. [1] [2] [3] [4] [5] In cell culture, 17␤ estradiol (E2) inhibits VSMC prolifera-tion. 6, 7 E2 also promotes the growth and migration of vascular endothelial cells, an essential aspect of vascular healing. 8 -11 
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The cardiovascular functions of estrogen depend on estrogen receptors ␣ and ␤ (ER␣ and ER␤; for review, see 12, and 13) . Mouse knockout studies have shown that ER␣ is required for estrogen-dependent protection from vascular injury 1 and from atherosclerosis 2 and that ER␤ is important for E2-mediated vasodilation, protection from age-related hypertension, and proper VSMC ion channel functioning. 14 ERs are transcription factors that, when bound by E2, bind to estrogen response elements and activate or repress target gene transcription. ERs can also be recruited to chromatin through interaction with other transcription factors, such as SP1, nuclear factor-B, and AP-1. 15, 16 We and others have shown that ERs, in the presence of estrogen, regulate many genes important for vascular biology. [17] [18] [19] [20] [21] [22] [23] In addition to their chromatin binding functions, agonistbound ERs also form signaling complexes in calveolae on the inner plasma membrane. 12,16,24 -27 Interactions between membrane-bound ERs and mediator proteins (including calveolin-1, shc, ras, striatin, MNAR, and G ␣i ) mediate the activation of several important cellular kinases, including c-Src, phosphatidylinositol-3 kinase, Akt, and the ERK1/2, JNK, and p38 mitogen-activated protein kinases, which regulate the activity of numerous downstream effectors. These pathways have been variously referred to as rapid, noncanonical, nonnuclear, or membrane-initiated ER signaling. For simplicity, we will refer to these effects of ER as the rapid pathway and to the functions of ER when bound to chromatin as the genomic pathway.
The overall functional importance of rapid ER signaling in the vascular gene regulatory and atheroprotective responses to estrogen has been largely unknown because of the absence of models for selective abrogation of this ER signaling pathway. We have shown previously that the adapter protein striatin interacts directly with ER␣ and that complex formation between ER␣ and striatin is required for the rapid signaling functions of ER. We previously identified the binding site within ER␣ that mediates striatin binding and demonstrated that overexpression of this peptide (amino acids 176 -253 of ER␣) disrupts ER/striatin complex formation and blocks mitogen-activated protein kinase, AKT, and endothelial nitric oxide synthase (eNOS) activation by E2 in cultured cells but does not prevent direct gene activation through ER binding to estrogen response elements. 28 In the present study, we develop a novel transgenic mouse that expresses this disrupting peptide (disrupting peptide mouse [DPM] ) and use this model to examine the functions of rapid signaling in mediating both the gene regulatory and physiological functions of estrogen in vascular cells and tissues.
Methods

Vectors and Adenoviruses
pCMV-ER176 -253-FLAG was created by cloning human ER␣ amino acids 176 to 253, which were previously shown to disrupt ER␣-striatin binding, in frame with the FLAG epitope tag in a cytomegalovirus promoter-driven expression plasmid (pCMV-Tag, Agilent). Adenovirus expressing ER176 -253-FLAG was generated by inserting polymerase chain reaction (PCR)-amplified ER176 -253-FLAG sequences into a cytomegalovirus promoter-containing pShuttle vector (Clontech), with virus production accomplished with the use of the Agilent Ad-Easy system. The striatin-short hairpin RNA (shRNA) vector was created by inserting the striatin shRNA sequences (forward: GATCCCCCAAGGTCGACAACTACTCA ttcaagagaTGAGTAGTTGTCGACCTTGTTTTTGGAAA;reverse: AGCTTTTCCAAAAACAAGGTCGACAACTACTCAtctcttgaa TGAGTAGTTGTCGACCTTGGGG) into pSUPER (OligoEngine). The eNOS-luciferase reporter was created by inserting the eNOS promoter sequences (from Ϫ1621) upstream of luciferase in the pGL3-basic reporter vector (Promega). The L7RH-␤-galactosidase control reporter, 29 cytomegalovirus promoter-ER␣ expression vector, 30 and adenovirus containing green fluorescent protein (GFP) (Ad-GFP) infection control vector 31 have been described previously.
Transgenic DPM Mouse Model
Ten C57Bl/6 females (3-4 weeks of age, from Jackson Labs) were each administered 5 IU of pregnant mare serum by intraperitoneal injection, followed by 5 IU of human chorionic gonadotropin 48 hours later. They were then mated with B6D2F1 stud males. The next day, 1-cell embryos were harvested from the donor females and injected with the pCMV-ER176 -253-FLAG vector at a concentration of 5 ng/L and cultured in drops of KSOM overnight at 37°C and 5% CO 2 . Five oviduct transfers of 30 two-cell embryos each were performed with the use of 0.5-day pseudopregnant C57Bl/6 foster females. Pups were genotyped from tail biopsies with the use of PCR with T3 and T7 primers flanking the insert. The integrity of the insert sequences was also confirmed with the use of the T3 and ER3615 (CCTGTTTTTATCAATGGTGCACTG) or T7 and ER3463 (CGCTAGTGTGCAGTGTGCAATGAC) insert-specific primer sets (data not shown). These studies used heterozygous (TGϩ/TGϪ) mice derived from BL6ϫDPM heterozygote matings. The colony used for all experiments was founded by mouse DPM2.
Cell Lines and Culture Methods
Aortic smooth muscle cells (SMCs) were cultured from aortic explants from wild-type (WT) and DPM mice 32 and grown in phenol red-free Dulbecco's modified Eagle's medium (DMEM) with 10% charcoal-stripped bovine growth serum (stripped bovine growth serum). EAhy926 cells (a human umbilical vein endothelial cell hybrid line, a kind gift of C.J. Edgell, University of North Carolina at Chapel Hill) were stably transfected with the striatin-shRNA vector or control empty vector (pSUPER). Twenty-four hours after transfection, cells were placed in selective media with puromycin at 5 g/mL (Sigma) for 2 to 3 weeks. Single colonies were selected from 96-well plates and maintained in the presence of 2 g/mL puromycin. Low-passage (Ͻ10) bovine aortic endothelial cells (BAECs) were cultured in DMEM with 10% fetal bovine serum (FBS), and human umbilical vein endothelial cells were cultured in M199, 10% bovine growth serum, 50 g/mL endothelial cell growth supplement (Biomedical Technologies), and 0.1 mg/mL heparin. BAECs were transfected with striatin-shRNA vector or vector alone by electroporation, followed by 1.5 g/mL puromycin selection for 48 hours, then a change to serum-free medium with puromycin for 24 hours, before treatment with E2 or FBS. Lung endothelial cells were isolated from WT and DPM mice by mixing anti-CD31-coated beads with a lung cell suspension. The sorted cells were growing in DMEMϩ10% bovine growth serumϩheparinϩendothelial cell growth supplement. When the cells were 60% to 75% confluent, a second sorting was performed with an anti-intercellular adhesion molecule-2 antibody. The doubly sorted cells were then grown as above, and endothelial cell purity was checked by eNOS immunostaining. To examine rapid E2 signaling, the cells were changed to low-serum medium (1% with no endothelial cell growth supplement) for 16 hours and to serum-free medium for 6 hours and treated with 10 nmol/L E2 or vehicle for 20 minutes before harvest. To measure eNOS protein induction, cells at Ϸ70% confluence were treated with 10 nmol/L E2 or vehicle for 16 hours in serum-free medium, and the medium was supplemented with low-serum medium (2%) for an additional 8 hours. This supplementation was necessary because we found that lung endothelial cells became visibly sick when starved of serum for Ͼ16 hours.
Coimmunoprecipitation and Immunodetection Methods
Coimmunoprecipitation assays were performed with the use of anti-ER␣ (H184, Santa Cruz Biotechnologies) or anti-ER␤ (Affinity BioReagents) antibodies, essentially as described in the report of Lu et al. 28 For Western blots, the following additional antibodies were used: anti-FLAG M2 (Sigma), anti-GAPDH (Calbiochem), HC20 anti-ER␣ (Santa Cruz Biotechnologies), and anti-striatin and anti-eNOS (BD Bioscience), with visualization with the use of anti-mouse or anti-rabbit-horseradish peroxidase secondary antibody (GE Healthcare UK LTD) and enhanced chemiluminescence (Amersham Pharmacia). For immunoflourescence assays, cultured primary aortic SMCs were fixed and stained with M2 antibody (1:500), with fluorescent detection with the use of donkey anti-mouse Cy3 (1:500; Jackson ImmunoResearch). Cells were counterstained with DAPI for visualization of the nucleus. COS-1 or cultured aortic SMCs transfected with ER176 -253-FLAG or ER␣ expression vectors were used as positive controls in Western blot and immunoflourescence assays.
Aortic SMC Growth Assays
Aortic SMCs from passages 7 to 10 were switched to media with 0.5% bovine growth serum for 18 hours, treated with 100 nmol/L E2 (Sigma) or EtOH vehicle for 30 minutes, and then treated with 20 ng/mL platelet-derived growth factor (Invitrogen) or 100 mmol/L acetic acid, 0.1% bovine serum albumin vehicle for 24 hours before RNA was harvested with the use of the RNeasy Plus kit (Qiagen). cDNA was prepared with the use of the Super Script VILO kit (Invitrogen), and quantitative reverse transcription PCR was performed with the use of QuantiTect SYBR Green (Qiagen) and the following primers: Pcna: forward CTAGCCATGGGCGTGAAC, reverse GAATACTAGTGCTAAGGTGTCTGCAT; and Gapdh: forward CAC-TGAAGGGCATCTTGG, reverse CATTGTCATACCAGGAAATGAG.
Migration Assays
P1 BAECs or human umbilical vein endothelial cells were grown to Ϸ85% confluence in a 6-well Biocoat plate (BD Biosciences) and infected with GFP (control) or ER␣176 -253-FLAG disrupting peptide adenovirus for 24 hours in serum-free medium. A single scratch "wound" was made with a plastic p200 tip. Cells were rinsed to remove nonadhered cells and incubated for 20 hours in media containing 10 nmol/L E2, 1 mol/L ICI-182780 (ICI, TOCRIS Bioscience) or EtOH vehicle, or 10% FBS. Cells were fixed in paraformaldehyde and stained with DAPI. Cell migration was measured as the number of DAPI-stained nuclei that had entered the scratch area (as demarcated by reference marks, with the use of photographs at time 0 versus 20 hours after scratching).
eNOS Expression Assays
Stable EAhy926 striatin knockdown or control cell lines were cotransfected with the eNOS-luciferase reporter, L7RH-␤galactosidase control reporter, 29 and cytomegalovirus-ER␣ expression 30 vectors with the use of Polyfect transfection reagent (Qiagen). After 24 hours, the medium was replaced with serum-free medium for 24 hours, and cells were treated with 10 nmol/L E2 and/or 100 nmol/L ICI, as indicated, for 24 hours before cell lysis. eNOS luciferase assay (Promega) counts were normalized by dividing by ␤galactosidase assay (Applied Biosystems) counts. Results for each cell line were then normalized to the vehicle-alone control (serumfree medium).
Carotid Artery Injury Model
The mouse carotid injury model used in this study has been described in detail previously. 1 Briefly, WT and DPM mice aged 8 to 12 weeks were ovariectomized at day Ϫ14 and randomly selected to receive either placebo pellets (ϪE2) or 17␤-estradiol-containing pellets (ϩE2; 0.25 mg/60-day release pellet, Innovative Research) at day Ϫ7. At day 0, the mice were anesthetized with inhaled isoflurane, and the left common carotid artery was denuded of its endothelium by intraluminal passage of a wire. At the same time, osmotic minipumps were implanted subcutaneously to release bromodeoxyuridine (BrdU; 25 mg/kg per day). At day 14, mice were euthanized for tissue and blood harvest. Both carotid arteries were harvested after perfusion fixation with 10% formalin and embedded in paraffin. Parallel sections were subjected to standard hematoxylin-eosin and elastin staining to measure medial area (the area between the internal and external elastic lamina) and to immunostaining with anti-BrdU Pure (BD Biosciences) to measure BrdU-positive dividing cells in the same region, as described previously. 1 All staining and subsequent analyses were performed in a fully blinded fashion. Medial area was measured as the area within the innermost and outermost elastic lamina in magnification ϫ20 images of elastin-stained sections, with the use of SPOT basic and ImagePro Plus software. Because an initial analysis indicated no evident or significant differences between ϩE2 and ϪE2 groups of uninjured arteries from the same strain (WT or DPM), these pairs of groups were combined in the analysis presented.
Microarray Expression Analysis
Aortas from WT and DPM mice were surgically removed from 10to 12-week-old female mice that had been ovariectomized 7 days before and treated ex vivo for 4 hours with either 10 nmol/L estradiol or ethanol vehicle (control). Four aortas were used for each group, with 2 groups for each ϩE2 condition (WT and DPM) and 3 groups for each ϩvehicle condition. RNA from each group was extracted from frozen tissue with TRIzol (Invitrogen), purified with the use of the RNeasy kit (Qiagen), and reverse transcribed to cDNA with the use of Superscript (Invitrogen). Labeling and hybridization to mouse genome 430A 2.0 microarrays (Affymetrix, Santa Clara, CA) were performed according to the Dana Farber core facility protocol (http://www.chip.dfci.harvard.edu/). Raw microarray data were normalized with the use of the GeneChIP robust microarray averaging method, and differential expression was analyzed with the use of Limma with array quality weighting. 33, 34 Three contrasts were performed, as follows: DPM_E2-DPM_vehicle (estrogen response in DPM); WT_E2-WT_ vehicle (estrogen response in WT); and (DPM_E2-DPM_vehicle)Ϫ(WT_E2-WT_vehicle) (differential estrogen response between DPM and WT). For each contrast, we selected genes having expression differences of Ͼ1.25-fold, with P values of Ͻ.02. Raw and processed data are available on GEO under accession number GSE35558.
Transcription Factor Binding Site Analysis
Promoter sequences, from Ϫ1000 to ϩ200 bp, for the 48 top differentially upregulated E2 genes and top 24 differentially downregulated genes (DPM_E2/V/WT_E2/V; PϽ0.01; fold change Ͼ1.25) were acquired from the University of California at Santa Cruz Genome Browser table lookup function (mouse mm9 genome). As a control, nonregulated set, we used Ϫ1000 to ϩ200 bp promoter sequences from the 3935 genes on the array that were expressed at least 1.1-fold greater than array background in all conditions and that showed Ͻ1.1-fold change in E2/vehicle in both WT and DPM aortas. We then performed Storm analysis as part of the CREAD package 35 to identify matches to the 585transcription factor binding site weight matrices in the TRANS-FAC database (courtesy of BIOBASE) with a functional depth of Ͼ0.85. The significance of overrepresentation or underrepresentation of binding sites in foreground versus background sets was assessed with the use of 2-tailed binomial tests corrected for multiple testing with the Benjamini-Hochberg method.
Statistical Analyses
Statistical analyses (for all but the aforementioned expression array and transcription factor binding site studies) were done with the use of SigmaStat and Excel software. Data from each experiment were first examined with a 2-way ANOVA to confirm significant deviation from the null hypothesis. Comparisons between pairs of conditions were then made with 2-tailed t tests and adjusted for multiple testing with the Benjamini-Hochberg method.
Results
Transgenic DPM mice carrying an expression construct for the FLAG-tagged ER␣176 -253 ER/striatin disrupting peptide were identified by PCR-based genotypic analysis of tail DNA ( Figure 1A ). ER␣176 -253-FLAG protein expression in liver was confirmed by Western blot against the FLAG epitope ( Figure 1B ). DPM mice are born in mendelian ratios, grow normally, are viable and fertile, and appear to be developmentally normal. By immunofluorescence, the peptide was found to be expressed throughout the cytoplasm and nucleus of cultured VSMCs isolated from the aortas of the transgenic mice ( Figure 1C ). The localization and expression levels observed were similar to those seen in SMCs infected with an adenovirus bearing the ER␣176 -253-FLAG expression construct ( Figure 1C , right). Expression of the ER␣176 -253 peptide blocked the ability of striatin to interact with ER␣ in coimmunoprecipitation assays in cells and tissues of the DPM mouse ( Figure 1D and data not shown).
Previously, we found that expression of the ER␣176 -253-FLAG peptide in EAhy926 endothelial cells blocked the E2-induced rapid phosphorylation of Akt and eNOS. 28 In the present study, we found that expression of the ER␣176 -253 in the DPM mouse also functionally blocks rapid signaling through ER␣, as evidenced by the E2-induced phosphorylation of Akt and ERK in WT-but not DPM-derived primary lung endothelial cells (Figure 2A ). To confirm that loss of rapid, E2-induced Akt phosphorylation resulted from loss of striatin binding, we transiently knocked down striatin in primary BAECs (average striatin protein levels reduced 68%; data not shown). We found that transient reduction of striatin expression in BAECs also resulted in loss of rapid phosphorylation of Akt ( Figure 2B ). Next, to facilitate studies of long-term estrogen responses in a transfectable cell model, we generated stable striatin knockdown and empty-vector control EAhy926 cells ( Figure 2C ) and showed that the striatin knockdown cells also lose E2-mediated induction of Akt phosphorylation ( Figure 2D ).
In addition to activating eNOS in endothelial cells via rapid ER signaling, E2 also upregulates expression of the eNOS gene via a transcriptional mechanism. 36, 37 To test whether rapid signaling was important for this upregulation, we examined the effects of E2 treatment on eNOS protein levels in the striatin knockdown versus control EAHy926 cells. We found that the E2-dependent increase in endogenous eNOS protein abundance observed in control cells was lost in the striatin knockdown cells ( Figure  3A ). Striatin knockdown did not, however, prevent the induction of eNOS protein levels by FBS. We also found that E2 activated an eNOS promoter-luciferase construct in control cell lines (an effect that was blocked by the ER antagonist ICI-182780) but not in the striatin knockdown cell lines ( Figure 3B ). In addition, whereas primary lung endothelial cells isolated from WT mice showed E2dependent induction of eNOS protein, this induction was lost in lung endothelial cells from DPM mice ( Figure 3C ). Taken together, these data indicate that, for eNOS and perhaps other endogenous ER target genes, rapid ER signaling modulates the gene regulatory effects of E2.
To more broadly test the hypothesis that rapid signaling is important for the transcriptional response of vascular tissues to estrogen, we performed expression microarray analysis in an aortic explant model. Briefly, female WT or DPM mice were ovariectomized, and aortas were harvested at day 7 and treated ex vivo with E2 or vehicle for 4 hours (in 2 to 3 groups of 4 mice per condition) before isolation of mRNA for expression array analysis. As in our prior studies, 22 we chose a 4-hour time point for this experiment to identify genes that were likely to be direct targets of ER signaling rather than targets of factors whose transcription was altered in firstwave responses. We used an aortic explant model to precisely control the timing and concentration of E2 in an intact vascular tissue. We found 243 genes that were significantly regulated by E2 treatment in WT aortas (165 upregulated and 78 downregulated; PՅ0.02 and fold-change Ն1.25; Figure   Figure 1 . Interactions between estrogen receptor (ER)␣ and striatin are blocked in a novel ER␣176 -253 disrupting peptide mouse (DPM). A, Tail DNA was amplified with the use of primers flanking the ER␣176 -253-FLAG insert, yielding an Ϸ480-bp transgene product; mice 66 and 69 were positive for the transgene. MW indicates molecular weight. B, The ER␣176 -253-FLAG peptide, as detected by anti-FLAG Western blot, is expressed in DPM but not wild-type (WT) liver cells. ϩCtrl indicates Cos-1 cells transfected with an ER␣176 -253-FLAG expression plasmid. C, Immunostaining for the disrupting peptide ER␣176 -253-FLAG (red) in mouse smooth muscle cells (SMCs). Insets show same image without overlay of blue DAPI nuclear stain. Ad-DP indicates adenovirus containing ER␣176 -253-FLAG peptide. D, Lysates from liver samples of 2 different DPM mice and 1 WT mouse were immunoprecipitated (IP) with anti-ER␣ antibody before Western blotting with antibodies to striatin or ER␣. Pos ctrl indicates positive control immunoprecipitation with both anti-ER␣ and anti-striatin antibodies from Cos-1 cells overexpressing ER␣; IgG ctrl, negative control immunoprecipitation with nonimmune IgG antibody.
4A, left) and 179 genes that were regulated by E2 treatment in DPM aortas (140 upregulated and 39 downregulated; Figure 4A , middle). Interestingly, the overlap between these sets was low, with only 27 genes being regulated in the same direction by E2 in both WT and DPM aortas ( Figure 4A , right).
Next we compared E2 responses in DPM mice (DPM_E2/ DPM_vehicle) with those in WT mice (WT_E2/WT_vehicle) and found that 151 genes showed significantly different E2 responses in DPM versus WT mice. We found that 101 of these showed higher E2-induced expression in DPM mice, whereas 50 showed higher E2-induced expression in WT mice ( Table I in the online-only Data Supplement) . Interestingly, as described further below and in the Discussion, many of these genes are of possible importance in vascular development, function, and disease (shaded in gray in Table I in the online-only Data Supplement). We classified the E2 responses for each differentially regulated gene as upregulated, downregulated, or nonregulated in each strain individually (WT or DPM), setting a fold change of Ͻ1.1 as nonregulated (see Table I in the online-only Data Supplement for fold change values). Strikingly, the results indicate that Ϸ50% of these differentially regulated genes showed opposing regulatory effects of E2 in the 2 mouse lines (eg, up in WT and down in DPM or vice versa; Figure 4B ). Almost all of the remaining differential response genes showed nonregulation in 1 strain and either upregulation or downregulation in the other. Interestingly, most of the differentially regulated genes (94 of 151) were either nonregulated or downregulated by E2 in WT mice and became upregulated by E2 in DPM mice (see Discussion).
Ingenuity pathway analysis of these differentially regulated genes indicated that they are significantly associated with CVD and development, cholesterol metabolism, HIF1 signaling, and endocrine system development and disorders ( Table  II in the online-only Data Supplement). We also examined ingenuity pathway analysis networks, which can suggest common regulatory mechanisms for subgroups of differentially regulated genes by showing the shortest physical or regulatory connections among these genes and between these genes and cellular kinases, transcription factors, and other proteins. Interestingly, many of the differentially regulated genes in these networks clustered around transcription factors that cooperate with ER at its binding sites or that are known Figure 2 . Rapid signaling is lost in cells from the disrupting peptide mouse (DPM) and in primary and immortalized cells lacking striatin. A, Primary lung endothelial cells from wild-type (WT) and DPM mice were progressively starved for serum over Ϸ12 hours before treatment with 10 nmol/L 17␤-estradiol (E2) or vehicle (Veh) for 20 minutes. The total cell lysates were immunoblotted with the indicated antibodies. B, Primary bovine aortic endothelial cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, and striatin expression was knocked down (KD) via transient short hairpin RNA transfection. Cells were grown for 24 hours in serum-free medium (SFM), then treated with vehicle (serum-free medium), 10 nmol/L E2, or 10% fetal bovine serum (FBS) for 20 minutes, and immunoblotted with the indicated antibodies. C, Western blot showing the reduction of striatin protein in stably transfected EAhy926 knockdown cell lines (striatin KD1 and striatin KD2) but not in an empty vector control cell line (Ctrl). Shown are results from 3 separate cultures derived from 2 independent clones for each cell line. Bottom, Immunoblots for ER␣ (showing that ER␣ protein levels are unaffected by striatin short hairpin RNAs) and for GAPDH (loading control). D, Stably-transfected striatin knockdown or empty vector control EAhy926 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, followed by treatment with serum-free medium for 24 hours, followed by treatment with 10 nmol/L E2 for 5 or 15 minutes. Cell lysates were immunoblotted for the indicated antibodies. Experiments were done in triplicate (for B and D) or quadruplicate (for A). BarsϭSD. *PϽ.05. Veh indicates vehicle treated; E2, 17␤-estradiol treated.
or potential targets for regulation by the kinases activated by rapid signaling (including nuclear factor-B [and the regulatory subunit of the IB kinase, IKBKG], Myc, Stat2, p53, HNF4␣, HNF1␣, and FoxE1) or around nuclear hormones and their receptors (including progesterone, AR, GR/NR3C1, and RAR␣; red circles in Figure 4C and Figures I through III in the online-only Data Supplement). Equally strikingly, most of the other differentially regulated genes in these networks were centered around kinases that are activated by rapid signaling, growth factors and their receptors, and mediators of inflammatory responses (including p38 mitogen-activated protein kinase, phosphatidylinositol-3 kinase, Akt, and Jnk; BMP6, platelet-derived growth factor BB, vascular endothelial growth factor, and the vascular endothelial growth factor receptor FLT1; and interferon␣, interferon␤, prostaglandin E2, and tumor necrosis factor). These observations are consistent with the hypothesis that the gene regulatory effects of rapid signaling proceed through modification of transcription factors by phosphatidylinositol-3 kinase, Akt, and mitogen-activated protein kinases and suggest the involvement of both previously implicated and novel transcription factors (see Discussion).
One possible explanation for the differential gene regulatory effects of E2 in WT versus DPM mice is that rapid signaling alters the activity of transcription factors that bind to consensus sequences in regulated promoters. To test this possibility, we searched the promoter regions (Ϫ1000 to ϩ200 bp) of the top 55 differentially upregulated genes (DPM_E2/DPM_vehicle Ͼ WT_E2/WT_vehicle; PϽ0.01; fold-change Ͼ1.25) or the top 28 differentially downregulated genes (DPM_E2/DPM_vehicle Ͻ WT_E2/WT_vehicle) for matches to 585 transcription factor binding site consensus matrices using Storm. 35 The site frequencies for this foreground data were then compared with site frequencies in a background set composed of the promoters of 3935 genes that were detectably expressed in aortas but were not regulated by E2 in either WT or DPM aortas. Consensus elements that were significantly overrepresented or underrepresented in each group are shown in Table III in the online-only Data Supplement. In the promoters of genes that were differentially upregulated by E2 in DPM aortas relative to WT, we found 27 transcription factor binding sites significantly overrepresented (including Stat4 and Stat5a sites) and 22 transcription factor binding sites significantly underrepresented (including SP1 sites). In the promoters of genes that are differentially downregulated by E2 in DPM compared with WT, we found 5 overrepresented transcription factor binding sites (including CEBP and Jun sites) and 4 underrepresented transcription factor binding sites (including AHR-HIF and p53).
The importance of rapid signaling on E2-dependent gene regulation suggests that rapid signaling might also be important for the physiological responses of vascular cells and tissues to estrogen. Prior cell culture studies have shown that estrogen can inhibit the growth of cultured SMCs, providing a likely cellular mechanism by which estrogen inhibits vascular remodeling in vivo. 6, 7 Consistent with those studies, we found that E2 significantly inhibited platelet-derived growth factor-stimulated proliferation of cultured mouse aortic SMCs derived from WT mice (PϽ0.01). However, E2 had no significant antiproliferative effect on DPM-derived aortic SMCs (with proliferation measured by proliferating cell nuclear antigen mRNA or cell count; Figure 5A and 5B). levels relative (Rel) to control GAPDH (with quantification below) in control or stably transfected striatin knockdown (KD) EAhy926 endothelial cell lines treated with serum-free medium (SFM) and vehicle (Veh), 10 nmol/L E2 (E2), or 10% fetal bovine serum (FBS) for 24 hours. B, E2 increases activity (act) of an eNOS-promoter luciferase reporter construct in transiently transfected control EAhy926 cells, and this effect is blocked by the estrogen receptor antagonist ICI-182780 (ICI). E2 had no effect on the eNOS promoter construct in stably transfected cells with striatin knockdown. C, Primary lung endothelial cells (ECs) from wild-type (WT) and DPM mice were treated with vehicle or 10 nmol/L E2 for 24 hours before Western blotting, as in A. Relative eNOS/␤-actin levels were normalized to WT and DPM vehicle controls. Experiments were done in triplicate (for B and C) or quadruplicate (for A). BarsϭSEM for A and SD for B and C. *PϽ0.05 relative to vehicle or serum-free medium controls.
E2 also stimulates migration of vascular endothelial cells, 9 -11 providing a second potential mechanism by which estrogen may protect against vascular injury. To examine the role of rapid signaling in this response, we infected BAECs with adenovirus carrying either the ER␣176 -253 disrupting peptide expression plasmid (Ad-DP) or a control GFP expression plasmid (Ad-GFP). We found that control BAECs showed significant migration to E2 that was blocked by the estrogen antagonist ICI ( Figure 5C ; BAECϩAd-GFP control set). By contrast, expression of ER␣176 -253 in BAECs blocked E2-stimulated migration ( Figure 5C ; BAECϩAd-DP). However, it did not block migration stimulated by FBS. Similar results were also seen in human umbilical vein endothelial cells, in which E2-induced migration was seen in Ad-GFP-infected cells but not in Ad-DP-infected cells (1.59fold versus 1.00-fold; nϭ4; PϽ0.008).
Finally, in our prior studies, we showed that E2 can inhibit VSMC proliferation and protect against carotid artery injury in vivo in WT but not in whole-body ER␣ knockout mice. 1 To determine whether rapid signaling plays a role in E2mediated vascular protection, we compared WT and DPM mice in the same carotid artery injury model ( Figure 6A ). Loops show self-regulatory homomultimerization events. Genes differentially upregulated or downregulated by E2, DPM vs WT, are shown in red and green, respectively, with log 2-fold change and P value below them. Complexes of multiple proteins are indicated by concentric circles. Nodes connected to many differentially regulated genes indicate proteins that may be involved in the coordinate regulation of these genes.
Strikingly, we found that E2 significantly decreased injuryinduced proliferation of SMCs in WT mice (as evidenced by a decreased number of BrdU-positive cells) but had no significant effect in the DPM mice ( Figure 6B , with quantification in Figure 6C ). Similarly, whereas estrogen treatment significantly inhibited injury-induced increases in the medial area in the WT mice, this effect was lost in DPM mice ( Figure  6D and 6E) .
Discussion
In the present study, we have used a novel model in which rapid ER signaling is inhibited by preventing striatin-ER interaction to show that rapid signaling plays an important role in mediating the transcriptional responses of aortic cells to E2 and is also required for several effects of estrogen on vascular cells and tissues, both in vitro and in vivo. With respect to transcription, we found that the transcriptional response of mouse aortas to E2 is greatly altered by the specific loss of rapid signaling through ER. This is consistent with previous studies showing a role for rapid signaling in the regulation of specific genes in various systems. 16, 24 It is also consistent with a recent study in human MCF7 breast cancer cells that found that approximately one quarter of the genes that are regulated by E2 are also regulated by estrogen dendrimer conjugates that cannot enter the nucleus and thus only activate the rapid pathway. 38 Taken together, these observations indicate that rapid signaling plays a major role in vascular gene regulatory responses to estrogen.
Approximately half of the differentially regulated genes showed opposite regulation by E2 in DPM versus WT mice, suggesting that rapid ER signaling may counter the regulatory effects of genomic signaling on gene expression, thus converting a normally stimulatory E2 response to a repressive response and vice versa. Such an effect could arise via rapid pathway kinases modifying and altering the functions of ER, ER coregulators, and/or transcription factors that cooperate with ER. For instance, mitogen-activated protein kinases, which are stimulated by rapid signaling, phosphorylate and activate ER␣ and ER␤, 39, 40 and E2 has also been shown to promote the activation of steroid receptor coactivator 3 by phosphorylation. 41 Furthermore, 93 of 151 differentially regulated genes went from downregulated or nonregulated in WT to upregulated in DPM, indicating that rapid signaling pathways may be particularly important for blocking activation and/or mediating repression through ER and E2.
Because mouse aortas are composed primarily of SMCs, the changes in mRNA levels we observe are likely to stem from regulatory effects in SMCs. This is likely to be one reason why eNOS induction by E2 in WT aortas was not as great as that observed in endothelial cells in culture. It is possible, however, that particularly strong E2 upregulatory events in the minority of aortic endothelial or adventitial cells could also be detected in our expression array analysis.
The simplest regulatory model for rapid signaling in E2 transcriptional response would be that transcription factors that are modified by rapid signaling kinases bind to DNA to activate or repress a distinct set of endogenous E2 target genes, which is independent from the set of genes regulated by ER binding to chromatin. However, if this were the case, we would expect that most differentially regulated genes would fall into the class of regulated in WT aortas and nonregulated in DPM mice. Surprisingly, however, relatively few genes had this characteristic (23 of 151; Figure 4B ). This indicates that the relationship between rapid signaling through membrane-bound ER and genomic signaling through chromatin-bound ER is much more complex, with the E2 Figure 5 . The estrogen receptor (ER)␣176 -253 striatin-blocking peptide eliminates the effect of 17␤-estradiol (E2) on smooth muscle cell growth and endothelial cell migration. A, Cultured aortic smooth muscle cells (AoSMCs) from wild-type (WT) and disrupting peptide mouse (DPM) mice were treated with E2 and/or platelet-derived growth factor (PDGF) as indicated. Cell growth relative to untreated controls was measured by quantitative reverse transcription polymerase chain reaction for the DNA-replication sliding clamp protein proliferating cell nuclear antigen (PCNA), whose expression is tightly coupled to cell growth, 7 with normalization to GAPDH. Each experiment was repeated 4 times, with 2 technical replicates per experiment. B, As in A, but with cell growth after 2 days measured by counting of trypsin-released cells with the use of a hemocytometer. The experiment was repeated twice with 3 technical replicates, and data were normalized to the vehicle (Veh) control value for WT or for DPM. C, Bovine aortic endothelial cells (BAECs) were infected with control adenovirus containing green fluorescent protein (Ad-GFP) or ER␣176 -253-FLAG peptide (Ad-DP) expression vectors and assayed for migration under the indicated conditions in a scratch-wound assay. FBS indicates fetal bovine serum. Each experiment was repeated 3 times, with 4 technical replicates. BarsϭSEM. *PϽ0.02; **PϽ0.001 (relative to EtOH control). response of most endogenous target genes determined by some combination of both ER functions. Indeed, one of the largest single classes (46 genes) was nonregulated in WT and became upregulated in DPM. These genes may represent targets at which rapid signaling normally functions to prevent a gene activation response mediated by ER binding to chromatin.
Through pathway and literature analysis, we found that many of the genes showing differential E2 responses in DPM versus WT aortas were associated with vascular function and disease. This suggests that the gene regulatory effects of rapid signaling might be important in mediating the physiological effects we observe for rapid signaling (promoting E2dependent endothelial cell migration and inhibiting VSMC growth both in vitro and in vivo). Differentially regulated genes that might play a role in these processes include the following: CNOT7, a protein involved in controlling cell proliferation that is upregulated in SMCs with contact 42 ; FLT1, a vascular endothelial growth factor receptor that is important for angiogenesis and is also upregulated in cancer, ischemia, and inflammatory disease 43, 44 ; and LTBP2, an extracellular transforming growth factor-␤ binding protein with roles in modulating the elasticity of the extracellular matrix. 45 In addition, several interferon-activated genes, including Ifit1, Ifit 2, and Ifit 3 and Rsad2, were upregulated in WT and downregulated in DPM, and these genes cluster around interferon nodes in ingenuity pathway analysis network 1. This suggests that rapid signaling promotes upregulation and counters downregulation of many interferonresponsive genes. We also found 3 differentially regulated genes that are involved in the metabolism of estrogen and other steroid hormones: HSD17B8/H2-Ke6, HSD17B10, and UGT1A1. Additional details for other genes of possible importance in mediating the vascular effects of rapid signaling are provided in Table I in the online-only Data Supplement (genes are highlighted in gray).
Interestingly, several of the transcription factor binding sites that we found to be enriched or underrepresented in differentially E2-responsive promoters (DPM versus WT) are known targets of rapid pathway signaling kinases (including SP1, STATs 4, 5, and 6, C/EBP, Elk1, and VJUN, which is related to the c-Jun component of AP-1). 16 Several were also found to be foci in top ingenuity pathway analysis networks (including STATs HNF4, p53, and myc), indicating that the relative enrichment of these transcription factor binding sites may contribute to the coordinate regulation of groups of genes by rapid signaling. Notably, there is considerable overlap between the differentially enriched transcription factors associated with rapid pathway-specific transcriptional responses and transcription factors that can cooperate with or recruit ER to chromatin (including SP1, Jun/AP-1, Stat5, and C/EBP). 16 This highlights the interconnectedness between rapid signaling to transcription factors and the genomic effects of ER binding to chromatin (at estrogen response elements or at cooperating transcription factor binding sites) and is consistent with the observation that relatively few genes were uniquely regulated by rapid signaling (eg, regulated by E2 in WT aortas and nonregulated in DPM aortas).
Factors whose sites are overrepresented on differentially downregulated promoters (those with decreased E2dependent transcription in DPM relative to WT), such as STAT4 and STAT5a, may normally function to activate transcription via rapid signaling, whereas sites overrepresented on differentially upregulated promoters (such as C/EBP) may normally repress transcription in response to rapid signaling. Conversely, factors whose sites are underrepresented in differentially regulated promoters may serve to counteract rapid pathway effects. For instance, the underenrichment of SP1 sites in differentially upregulated promoters suggests that SP1 (perhaps through its ability to recruit ER to chromatin 16 ) may block gene repression through rapid ER signaling.
Strikingly, expression of the disrupting peptide in DPM mice eliminated the protective effect of E2 in a carotid artery injury model, blocking the E2-mediated decrease in medial thickening and the number of BrdU-positive dividing cells (2 measures of VSMC growth and proliferation in response to injury). These observations fit well with recent findings from a complementary model, in which selective activation of rapid signaling by estrogen dendrimer conjugates was found to inhibit SMC growth and enhance endothelial cell regrowth, in a similar arterial injury model, as efficiently as E2 . 46 The consistent interpretation between both of these model systems (selective inhibition resulting in loss of E2 protection and selective activation resulting in protection similar to that of E2) indicates that rapid signaling through ERs is both necessary and sufficient for some of the most important vasoprotective effects of estrogen. We also found that abrogation of rapid signaling through ER blocks 2 positive cellular responses to estrogen, eliminating both E2-mediated inhibition of cultured VSMC growth and E2-mediated stimulation of endothelial cell migration, suggesting cellular mechanisms by which rapid signaling may mediate the protective effects of E2 in vascular injury. It is worth noting that these cell culture studies employed a single 10-nmol/L concentration of E2 in the absence of growth factors from serum, similar to many prior studies of estrogen function. It will be important, however, for future studies to consider the effects of lower-nanomolar E2 concentrations (more typical of circulating estrogen levels in nonpregnant animals) alone or in combination with growth hormones that can also influence ER activity. 15, 16 We have shown previously that whole-body ER␣ knockout mice lose the protective effects of E2 in the same carotid artery injury model used here. 1 Considered together with our present observations in DPM mice, this suggests that the protection from vascular injury afforded by E2 may require rapid signaling specifically through ER␣. It is important to note, however, that vascular tissues also express ER␤, and we found that striatin interacts to a similar extent with ER␤ and ER␣ in coimmunoprecipitation experiments and even directly as purified proteins ( Figure IV in the online-only Data Supplement). Thus, although the loss of E2-dependent protection from vascular injury in DPM mice may be largely mediated through ER␣, either or both of ER␣ or ER␤ may mediate other effects that result from inhibition of rapid signaling, including alterations in E2-dependent gene regulation and loss of E2-stimulated endothelial cell migration.
Considered all together, these data indicate that rapid signaling through ERs is of critical importance in mediating the vascular protective effects of estrogen. As such, we anticipate that an increased understanding of the mechanisms of rapid signaling, as well as its effects on both cell physiology and gene regulation, could facilitate the development of novel pathway-selective ER␣ activators as therapies to promote vascular health.
